XOFIGO- Ra-223 Chloride for Palliation of Pain from Bony Metastases

Course overview

XOFIGO is approved for palliation of pain in patients with castration-resistant prostate cancer. This tutorial reviews the physical, chemical, and biological properties as well its mode of decay, describes the clinical indication for use of XOFIGO, reviews the eligibility requirements for qualifying a patient for a XOFIGO study; gives an overview of the administration procedure and frequency of injections. It also reviews the contraindications for performing the procedure and describes the procedure for determining dose volume. In addition, it lists possible adverse reactions and side effects and their frequency of occurrence Finally, it covers internal radiation dosimetry associated with XOFIGO and includes Kaplan-Meyer curves for overall survival based on clinical results.